Please ensure Javascript is enabled for purposes of website accessibility

4 Reasons Why Canopy Growth Could Bounce Back in 2020

By David Jagielski – May 28, 2020 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pot stock's been struggling over the past year, but there are plenty of reasons to be optimistic about its future.

Ontario-based pot producer Canopy Growth (CGC 4.41%) has struggled over the past year, with its share price down about 55%. The only consolation for Canopy investors is that the Horizons Marijuana Life Sciences ETF (HMLSF -8.37%) has performed even worse during that period, falling by more than 60%.

But there is hope that this company, which is often seen as the industry leader, could turn things around this year. There are several reasons to be bullish on Canopy Growth's stock in 2020, and why it could rise in the coming months.

1. It's got a new CEO

The biggest reason I'm bullish on Canopy Growth is that it's got a new CEO in charge this year: David Klein, who came over from Constellation Brands (STZ -2.25%). The beer company is a key investor in Canopy Growth, and earlier this month it upped its stake in the pot producer to 38.6% after exercising warrants.

Cannabis greenhouse.

Image source: Getty Images.

Being optimistic about a new leader is no disrespect to Bruce Linton, either; Canopy Growth's former CEO built the company up into the big-name pot stock that it is today. But Klein was a CFO at Constellation, and as a finance-oriented guy, he'll focus on pruning the company's expenses and making it a more investable company.

And cutting costs is what he's been doing of late. In April, the company laid off 200 of its retail workers and announced that it would be scaling back some of its international operations in an effort at streamlining. These changes will help save money and strengthen the company's financial health -- which leads into an important reason why the stock could soar this year.

2. Canopy Growth's financials could look a lot stronger in 2020

Profitability in the industry is key, not only to appeal to investors but to make operations sustainable, which is particularly important during COVID-19.

While Canopy Growth had more than 1.5 billion Canadian dollars in cash on its books as of Dec. 31, it doesn't want to be burning through all that money. And with the moves Klein's been making, there's reason to be optimistic that not only will the company's cash flow improve, but it'll get closer to breaking even as well.

In the company's third-quarter earnings, released Feb. 14, Canopy Growth incurred a loss of CA$124.2 million. It has now been in the red in seven of its past eight quarters. It's also burned through cash from its day-to-day operating activities in each of the last 10 quarters.

But investors should expect to see some improvement in the pot producer's financial statements this year as a result of the moves Klein's been making. The one caveat, however, is that COVID-19 could negatively affect the company's sales, which would likely weigh down Canopy Growth's overall performance.

When the company releases its fourth-quarter results Friday, investors may start to see some early signs of the company's progress.

3. The stock's at a more reasonable valuation

Canopy Growth's stock is nowhere near its 52-week high of more than $45 a share. And that's a good thing for investors who invest in the stock this year. With the stock trading at about 22 times its sales, it has a much better valuation than in the past:

CGC PS Ratio Chart

CGC PS Ratio data by YCharts

Its price-to-sales ratio suggests the stock is a bargain compared to where it's been trading over the past three years. While there's the potential that it could continue to fall given the volatility in the sector, the stock's definitely much better positioned for a rally today than it was a year ago, when it was trading at well over 50 times its sales.

4. Canopy Growth's a safe buy in a risky industry

Whether it's due to COVID-19 or just a lack of cash, investors could see many pot stocks go out of business this year as they struggle to raise money and keep their operations running, much less growing. Canopy Growth isn't in that situation. It has plenty of cash on its books, it's cutting costs, and it has a key partner in Constellation Brands that can help provide support. With a large stake in the cannabis company, Constellation's more committed than ever to seeing Canopy Growth succeed.

And as investors worry about whether the pot stock they've invested in might go under, Canopy Growth will remain a safe alternative. By default, the company could attract a lot of interest from cannabis investors who want to take on a bit less risk, especially during a pandemic that's sent the markets on a roller-coaster ride this year.

The bottom line

There are many good reasons to be bullish on Canopy Growth right now. But just how far the pot stock will rise this year will ultimately depend on not only the success of its own business, but how bullish investors are in the cannabis industry as a whole. The latter may be out of Canopy Growth's control, but the former isn't. And as long as the company's continuing to do well, the stock should be a safe bet to outperform its peers and have a strong year in 2020.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
$2.84 (4.41%) $0.12
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
$231.26 (-2.25%) $-5.33
Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
$4.49 (-8.37%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.